Evolvere BioSciences (YC S24) — Making Next-Generation antibiotics that outpace bacterial evolution
🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops.
Evolvere BioSciences is a Y Combinator company in the Summer 2024 batch. Its directory entry describes it as: Making Next-Generation Antibiotics that Outpace Bacterial Evolution. The founders listed are Adam Winnifrith (Founder/CEO), Piotr Jedryszek (Founder/CTO), Weronika Slesak (Founder) (Y Combinator directory entry, August 16, 2024).
Get an email when Evolvere BioSciences changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells.
☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈.
🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩⚕️.
We are a team of biochemists and evolutionary biologists who met at the University of Oxford.
Adam Winnifrith
Founder/CEO
Piotr Jedryszek
Founder/CTO
Weronika Slesak
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 65 companies held here in Healthcare › Therapeutics.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Evolvere BioSciences?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Evolvere BioSciences: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evolvere BioSciences covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Evolvere BioSciences: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
